Literature DB >> 26171018

Recurrent waist tumor subsequent to percutaneous nephrolithotomy: A case report.

Shusuan Jiang1, Sulai Liu2, Pingping Tan3, Tieyong Song1, Y U Xie1, Fuhua Zeng1, Zhizhong Liu1, Weiqing Han1, Zengnan Mo4, Lin Qi5.   

Abstract

The present study reports the case of a 39-year old male patient with a recurrent waist tumor that occurred subsequent to percutaneous nephrolithotomy (PCNL). The patient initially underwent PCNL for the management of right calculus of the kidney. Six years later, the patient underwent local mass resection for a tumor at the waist, which was subsequently diagnosed as adenocarcinoma. However, seven months subsequent to local resection, the patient presented to the Affiliated Cancer Hospital of Xiangya Medical School with a one-month history of a recurrent tumor located at the right waist. Physical examination identified no visible skin lesions; however, a palpable hard nodule was present over the right waist. Imaging studies, consisting of computed tomography (CT) and positron emission tomography-CT, indicated no additional metastases. Therefore, the patient underwent local mass resection of the waist tumor. Subsequent histological examination determined a diagnosis of metastatic adenocarcinoma. Considering the previously conducted PCNL surgery and the diagnosis, it is proposed that the recurrent waist tumor originated from renal cell carcinoma (RCC), also termed renal adenocarcinoma. However, no evidence of the original RCC tumor was identified. Therefore, the selection of an effective treatment strategy was challenging.

Entities:  

Keywords:  percutaneous nephrolithotomy; renal cell carcinoma; waist tumor

Year:  2015        PMID: 26171018      PMCID: PMC4487090          DOI: 10.3892/ol.2015.3175

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  13 in total

1.  Percutaneous pyelolithotomy. A new extraction technique.

Authors:  I Fernström; B Johansson
Journal:  Scand J Urol Nephrol       Date:  1976

Review 2.  Risk factors for sepsis after percutaneous renal stone surgery.

Authors:  Evgeniy I Kreydin; Brian H Eisner
Journal:  Nat Rev Urol       Date:  2013-09-03       Impact factor: 14.432

Review 3.  Complications in percutaneous nephrolithotomy.

Authors:  Maurice Stephan Michel; Lutz Trojan; Jens Jochen Rassweiler
Journal:  Eur Urol       Date:  2006-10-25       Impact factor: 20.096

4.  Current practices in percutaneous nephrolithotomy among endourologists.

Authors:  Sri Sivalingam; Shannon T Cannon; Stephen Y Nakada
Journal:  J Endourol       Date:  2014-01-31       Impact factor: 2.942

Review 5.  Standardization of patient outcomes reporting in percutaneous nephrolithotomy.

Authors:  Dedan Opondo; Stavros Gravas; Andrian Joyce; Margaret Pearle; Tadashi Matsuda; Ying-Hao Sun; Dean Assimos; John Denstedt; Jean de la Rosette
Journal:  J Endourol       Date:  2014-04-16       Impact factor: 2.942

6.  Renal cell carcinoma seeding of a percutaneous biopsy tract.

Authors:  Jeffrey K Mullins; Ronald Rodriguez
Journal:  Can Urol Assoc J       Date:  2013 Mar-Apr       Impact factor: 1.862

7.  Nephrostomy tract tumor seeding following percutaneous manipulation of a ureteral carcinoma.

Authors:  A Huang; R K Low; R deVere White
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

8.  Renal cell cancer stage migration: analysis of the National Cancer Data Base.

Authors:  Christopher J Kane; Katherine Mallin; Jamie Ritchey; Matthew R Cooperberg; Peter R Carroll
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

9.  Seeding of malignant renal tumor through a nephrostomy tract.

Authors:  Shian-Shiang Wang; Hao-Chung Ho; Chung-Kwang Su; Wen-Ming Chen; Chen-Li Cheng; Chi-Rei Yang
Journal:  J Chin Med Assoc       Date:  2004-06       Impact factor: 2.743

10.  Percutaneous nephrolithotomy: short- and long-term effects on health-related quality of life.

Authors:  Daniel Adolfo Pérez-Fentes; Francisco Gude; Benito Blanco; Camilo García Freire
Journal:  J Endourol       Date:  2015-01       Impact factor: 2.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.